Journal: Materials Today Bio

Article Title: Astragalin-functionalized ultrasmall nanoparticles modulate the complement pathway to inhibit microglial synaptic phagocytosis for reducing anesthetic neurotoxicity

doi: 10.1016/j.mtbio.2025.101714

Figure Lengend Snippet: (a) Representative confocal microscopy images of C1q in BV2 cells treated with CSP (0.25 mM), AS (0.01 mM), or CSPA NPs (0.25 mM) for 12 h after sevoflurane exposure (scale bar = 20 μm). (b) Immunofluorescence analysis of C1q expression in BV2 cells treated with CSP (0.25 mM), AS (0.01 mM), or CSPA NPs (0.25 mM) for 12 h after sevoflurane exposure (n = 6). (c) Representative confocal microscopy images showed the C3 expression in BV2 cells treated with CSP (0.25 mM), AS (0.01 mM), or CSPA NPs (0.25 mM) for 12 h after sevoflurane exposure (scale bar = 20 μm). (d) Quantification of C3 expression in BV2 cells treated with CSP (0.25 mM), AS (0.01 mM), or CSPA NPs (0.25 mM) for 12 h after sevoflurane exposure (n = 6). (e, f) Western blot analysis of C1qa and C3 in BV2 cells treated with different concentrations of CSPA NPs for 12 h after sevoflurane exposure (n = 5). (g, h) Western blot analysis of C3 in BV2 cells treated with CSP (0.25 mM), AS (0.01 mM), or CSPA NPs (0.25 mM) for 12 h after sevoflurane exposure (n = 5). (i, j) Western blot analysis of C1qa in BV2 cells treated with CSP (0.25 mM), AS (0.01 mM), ANX (0.1 mM), or CSPA NPs (0.25 mM) for 12 h after sevoflurane exposure (n = 5). (k) Representative confocal microscopy images of fluorescent beads (red) in BV2 cells treated with CSP (0.25 mM), AS (0.01 mM), or CSPA NPs (0.25 mM) for 12 h after sevoflurane exposure. The results showed that CSPA NPs significantly reduced the phagocytosis of fluorescent beads by BV2 cells after sevoflurane exposure (scale bar = 20 μm). (l) Representative confocal microscopy images of BV2 cells (IBA1 + , red) cocultured with HT22 cells (NeuN + , green) treated with CSP (0.25 mM), AS (0.01 mM), or CSPA NPs (0.25 mM) for 12 h after sevoflurane exposure. The results showed that CSPA NPs significantly reduced BV2 cells' phagocytosis of synapses after sevoflurane exposure (scale bar = 20 μm). Two-way ANOVA followed by a post hoc Tukey's test was used for comparisons among multiple groups. The data were presented as the mean ± SEM. ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001.

Article Snippet: The primary antibodies used were as follows: PSD95 (1:200, 381001, ZENBIO), PSD95 (1:200, ab12093, Abcam), Vglut2 (1:200, NBP2-59330, NOVUS), C1q (1:200, DF7839, Affinity), C1q (1:200, 67063-1, Proteintech), IBA1 (1:400, ab283342, Abcam), CD68 (1:200, 29176, CST), CD11b (1:200, R380675, ZENBIO), C3 (1:200, 21337-1-AP, Proteintech), C3 (1:200, PA1-29715, Invitrogen), PGRN (1:200, abs137474, Absin), TFEB (1:200, AG3609, Beyontime), sortilin (1:200, 12369-1-AP, Proteintech), and NeuN (1:200, 26975-1-AP, Proteintech).

Techniques: Confocal Microscopy, Immunofluorescence, Expressing, Western Blot

Journal: Materials Today Bio

Article Title: Astragalin-functionalized ultrasmall nanoparticles modulate the complement pathway to inhibit microglial synaptic phagocytosis for reducing anesthetic neurotoxicity

doi: 10.1016/j.mtbio.2025.101714

Figure Lengend Snippet: (a) Representative confocal microscopy images and 3D rendering of IBA1 + (red) microglia in the hippocampal CA1 region of mice in the Con + PBS group, Sev + PBS group, Sev + PBS + US group, Sev + CSPA@CM group, and Sev + CSPA@CM + US group (scale bar = 20 μm). (b) Skeleton analysis of microglial morphology in the five groups of mice (n = 20). (c, d) Representative confocal microscopy images and colocalization analysis of IBA1 (red) and CD68 (green) in the CA1 region of mice from the five groups (scale bar = 20 μm, n = 6). (e–h) Representative confocal microscopy images and analysis of the expressions of C1q and C3 in the five groups of mice (scale bar = 5 μm, n = 6). (i, j) Western blot analysis of the expressions of C1qa and C3 in mice from the four groups of mice (n = 5). Two-way ANOVA followed by a post hoc Tukey's test was used for comparisons among multiple groups. The data were presented as the mean ± SEM. ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001.

Article Snippet: The primary antibodies used were as follows: PSD95 (1:200, 381001, ZENBIO), PSD95 (1:200, ab12093, Abcam), Vglut2 (1:200, NBP2-59330, NOVUS), C1q (1:200, DF7839, Affinity), C1q (1:200, 67063-1, Proteintech), IBA1 (1:400, ab283342, Abcam), CD68 (1:200, 29176, CST), CD11b (1:200, R380675, ZENBIO), C3 (1:200, 21337-1-AP, Proteintech), C3 (1:200, PA1-29715, Invitrogen), PGRN (1:200, abs137474, Absin), TFEB (1:200, AG3609, Beyontime), sortilin (1:200, 12369-1-AP, Proteintech), and NeuN (1:200, 26975-1-AP, Proteintech).

Techniques: Confocal Microscopy, Western Blot

Journal: Cell Reports Medicine

Article Title: Phenotypic plasticity and increased infiltration of peripheral blood-derived TREM1 + mono-macrophages following radiotherapy in rectal cancer

doi: 10.1016/j.xcrm.2024.101887

Figure Lengend Snippet: Differentiation of CCR2 + TREM1 high mono-macrophages in the SIC-treated tumor microenvironment (A) The trajectory distribution of each mono-macrophage population over time in all samples. The dark color above is the starting point of development, and the light color below is the development endpoint (left). Each subset was marked with a different color (right). (B) The trajectory distribution of TREM1 expression in mono-macrophage cell population. (C) The TREM1 expression in mono-macrophages at different time point, which were isolated from human peripheral blood mononuclear cells (PBMCs) treated with HCT116 cell supernatants with different treatment as indicated, n = 3 biological repeats. Statistical analysis was performed using one-way ANOVA with Tukey’s correction. Error bars depict means ± SEM. ∗∗∗∗ p < 0.0001. (D) Volcano plot demonstrating differentially expressed genes in C1QC + CD163 high tumor-associated macrophage (TAM) and C1QC + CD163 low TAM in tumor tissues after SIC treatment. Relevant genes were highlighted. (E) Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis of C1QC + CD163 high TAM and C1QC + CD163 low TAM in tumor tissues after SIC treatment.

Article Snippet: Mouse C1qC Monoclonal antibody , Proteintech , Cat# 66268-1-Ig; RRID: AB_2881653.

Techniques: Expressing, Isolation

Journal: Cell Reports Medicine

Article Title: Phenotypic plasticity and increased infiltration of peripheral blood-derived TREM1 + mono-macrophages following radiotherapy in rectal cancer

doi: 10.1016/j.xcrm.2024.101887

Figure Lengend Snippet:

Article Snippet: Mouse C1qC Monoclonal antibody , Proteintech , Cat# 66268-1-Ig; RRID: AB_2881653.

Techniques: Purification, Recombinant, Staining, Cell Isolation, Isolation, Software, Sequencing, Flow Cytometry, Real-time Polymerase Chain Reaction

Journal: Scientific reports

Article Title: Complement classical and alternative pathway activation contributes to diabetic kidney disease progression: a glomerular proteomics on kidney biopsies.

doi: 10.1038/s41598-024-84900-4

Figure Lengend Snippet: Fig. 3. Immunohistochemistry (IHC) staining for C1q, C3, C4, C5b-9, CFB, CFH, MBL, and MASP. (a–e) Representative images of C1q, C3, C4, C5b-9, and CFB staining showing a GBM pattern of immunostaining in kidney tissues from patients with DKD. (f) Immunohistochemical diagram of CFH in kidneys with DKD depicting mesangial deposition. (g, h) Representative images of MBL and MASP staining showing no deposition was found in the glomeruli of kidneys with DKD. Scale bars represent 50 μm. CFB, complement factor B; CFH, complement factor H; MBL, mannose-binding lectin; MASP, mannose-binding lectin- associated serine protease; GBM, glomerular basement membrane; DKD, diabetic kidney disease.

Article Snippet: After washing, sections were incubated with either anti-C1q antibodies (1:200 dilution, 16889-1-AP; Proteintech), anti-C3 antibodies (1:200 dilution, ab200999; Abcam), anti-C4 antibodies (1:300 dilution, 22233-1-AP; Proteintech), anti-C5b-9 antibodies (1:400 dilution, ab55811; Abcam), anti-MBL antibodies (1:200 dilution, ab23457; Abcam), anti-MASP1 antibodies (1:400 dilution, 21837-1-AP; Proteintech), anti-CFB antibodies (1:50 dilution, ab192577; Abcam), or anti-CFH antibodies (1:50 dilution, ab170036; Abcam) overnight at 4 °C in a moist chamber.

Techniques: Immunohistochemistry, Staining, Immunostaining, Immunohistochemical staining, Binding Assay, Membrane